-
市場
-
產品
-
資訊
-
Moo社區
-
課堂
-
查看更多
-
功能介紹
-
費用費用透明,無最低余額限制
投資選擇、功能介紹、費用相關信息由Moomoo Financial Inc.提供
- English
- 中文繁體
- 中文简体
- 深色
- 淺色
Things Look Grim For Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) After Today's Downgrade
Things Look Grim For Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) After Today's Downgrade
Today is shaping up negative for Jacobio Pharmaceuticals Group Co., Ltd. (HKG:1167) shareholders, with the analysts delivering a substantial negative revision to this year's forecasts. Revenue and earnings per share (EPS) forecasts were both revised downwards, with analysts seeing grey clouds on the horizon. Surprisingly the share price has been buoyant, rising 19% to HK$5.25 in the past 7 days. Whether the downgrade will have a negative impact on demand for shares is yet to be seen.
After the downgrade, the two analysts covering Jacobio Pharmaceuticals Group are now predicting revenues of CN¥175m in 2022. If met, this would reflect a solid 17% improvement in sales compared to the last 12 months. Losses are supposed to balloon 21% to CN¥0.46 per share. Yet prior to the latest estimates, the analysts had been forecasting revenues of CN¥200m and losses of CN¥0.41 per share in 2022. So there's been quite a change-up of views after the recent consensus updates, with the analysts making a serious cut to their revenue forecasts while also expecting losses per share to increase.
Check out our latest analysis for Jacobio Pharmaceuticals Group
SEHK:1167 Earnings and Revenue Growth August 26th 2022The consensus price target fell 9.4% to CN¥11.15, with the analysts clearly concerned about the company following the weaker revenue and earnings outlook. It could also be instructive to look at the range of analyst estimates, to evaluate how different the outlier opinions are from the mean. There are some variant perceptions on Jacobio Pharmaceuticals Group, with the most bullish analyst valuing it at CN¥19.09 and the most bearish at CN¥6.46 per share. We would probably assign less value to the forecasts in this situation, because such a wide range of estimates could imply that the future of this business is difficult to value accurately. As a result it might not be possible to derive much meaning from the consensus price target, which is after all just an average of this wide range of estimates.
Of course, another way to look at these forecasts is to place them into context against the industry itself. One thing stands out from these estimates, which is that Jacobio Pharmaceuticals Group is forecast to grow faster in the future than it has in the past, with revenues expected to display 17% annualised growth until the end of 2022. If achieved, this would be a much better result than the 72% annual decline over the past year. By contrast, our data suggests that other companies (with analyst coverage) in a similar industry are forecast to see their revenue grow 40% per year. Although Jacobio Pharmaceuticals Group's revenues are expected to improve, it seems that the analysts are still bearish on the business, forecasting it to grow slower than the broader industry.
The Bottom Line
The most important thing to note from this downgrade is that the consensus increased its forecast losses this year, suggesting all may not be well at Jacobio Pharmaceuticals Group. Unfortunately analysts also downgraded their revenue estimates, and industry data suggests that Jacobio Pharmaceuticals Group's revenues are expected to grow slower than the wider market. With a serious cut to this year's expectations and a falling price target, we wouldn't be surprised if investors were becoming wary of Jacobio Pharmaceuticals Group.
As you can see, the analysts clearly aren't bullish, and there might be good reason for that. We've identified some potential issues with Jacobio Pharmaceuticals Group's financials, such as recent substantial insider selling. For more information, you can click here to discover this and the 2 other concerns we've identified.
Another way to search for interesting companies that could be reaching an inflection point is to track whether management are buying or selling, with our free list of growing companies that insiders are buying.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
今天對我們來説是負面的雅可比奧製藥集團有限公司(HKG:1167)股東,分析師大幅下調今年的預測。營收和每股收益(EPS)預期雙雙下調,分析師認為地平線上將出現烏雲。令人意外的是,該公司股價一直很高,在過去7天裏上漲了19%,達到5.25港元。評級下調是否會對股票需求產生負面影響還有待觀察。
在評級下調後,負責雅可比奧製藥集團的兩位分析師現在預測,2022年收入將達到1.75億加元。如果得到滿足,這將反映出與過去12個月相比,銷售額穩步增長了17%。預計虧損將激增21%,至每股0.46元。然而,在最新估計之前,分析師們一直預測2022年營收為2億加元,每股虧損0.41元。因此,在最近的共識更新之後,人們的觀點發生了相當大的變化,分析師們大幅下調了收入預期,同時預計每股虧損將會增加。
查看我們對Jacobio製藥集團的最新分析
聯交所:1167盈利及收入增長2022年8月26日目標股價下跌9.4%,至11.15加元,分析師顯然對該公司感到擔憂,此前該公司營收和盈利前景較弱。看看分析師估計的範圍,評估異常值與平均值的差異也可能是有啟發意義的。對Jacobio PharmPharmticals Group有一些不同的看法,最樂觀的分析師對其估值為19.09加元,最悲觀的分析師估值為每股6.46元。在這種情況下,我們可能會對預測給予較低的價值,因為如此大的估計範圍可能意味着,這項業務的未來很難準確估值。因此,可能不可能從共識價格目標中獲得太大意義,畢竟這只是這一廣泛估計範圍的平均值。
當然,看待這些預測的另一種方式是將它們放在與行業本身相反的背景下。從這些估計中有一件事引人注目,那就是Jacobio PharmPharmticals Group預計未來的增長速度將快於過去,預計到2022年底,收入將出現17%的年化增長。如果實現,這將比過去一年72%的年降幅要好得多。相比之下,我們的數據顯示,類似行業的其他公司(有分析師覆蓋)的收入預計將以每年40%的速度增長。儘管Jacobio PharmPharmticals Group的收入預計將有所改善,但分析師似乎仍看空該業務,預計其增長速度將慢於更廣泛的行業。
底線
從這次降級中需要注意的最重要的一件事是,共識增加了今年的預測虧損,這表明雅各比奧製藥集團可能並不是一切都好。不幸的是,分析師也下調了他們的營收預期,行業數據顯示,雅可比奧製藥集團的營收增長預計將慢於更廣泛的市場。隨着今年預期的大幅下調和目標價的下降,如果投資者對雅各比奧製藥集團變得謹慎起來,我們也不會感到驚訝。
正如你所看到的,分析師們顯然並不看好股市,這或許是有充分理由的。我們已經發現了雅各比奧製藥集團的一些潛在財務問題,例如最近的大規模內幕銷售。有關更多信息,您可以單擊此處瞭解這一點以及我們確定的其他兩個問題。
搜索有趣的公司的另一種方式可能是到達拐點是跟蹤管理層是在買入還是在賣出,我們的免費內部人士正在收購的成長型公司名單。
對這篇文章有什麼反饋嗎?擔心內容嗎? 保持聯繫直接與我們聯繫。或者,也可以給編輯組發電子郵件,地址是implywallst.com。
本文由Simply Wall St.撰寫,具有概括性。我們僅使用不偏不倚的方法提供基於歷史數據和分析師預測的評論,我們的文章並不打算作為財務建議。它不構成買賣任何股票的建議,也沒有考慮你的目標或你的財務狀況。我們的目標是為您帶來由基本面數據驅動的長期重點分析。請注意,我們的分析可能不會將最新的對價格敏感的公司公告或定性材料考慮在內。Simply Wall St.對上述任何一隻股票都沒有持倉。
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
風險及免責聲明
moomoo是Moomoo Technologies Inc.公司提供的金融資訊和交易應用程式。
在美國,moomoo上的投資產品和服務由Moomoo Financial Inc.提供,一家受美國證券交易委員會(SEC)監管的持牌主體。 Moomoo Financial Inc.是金融業監管局(FINRA)和證券投資者保護公司(SIPC)的成員。
在新加坡,moomoo上的投資產品和服務是通過Moomoo Financial Singapore Pte. Ltd.提供,該公司受新加坡金融管理局(MAS)監管(牌照號碼︰CMS101000) ,持有資本市場服務牌照 (CMS) ,持有財務顧問豁免(Exempt Financial Adviser)資質。本內容未經新加坡金融管理局的審查。
在澳大利亞,moomoo上的金融產品和服務是通過Futu Securities (Australia) Ltd提供,該公司是受澳大利亞證券和投資委員會(ASIC)監管的澳大利亞金融服務許可機構(AFSL No. 224663)。請閱讀並理解我們的《金融服務指南》、《條款與條件》、《隱私政策》和其他披露文件,這些文件可在我們的網站 https://www.moomoo.com/au中獲取。
在加拿大,透過moomoo應用程式提供的僅限訂單執行的券商服務由Moomoo Financial Canada Inc.提供,並受加拿大投資監管機構(CIRO)監管。
在馬來西亞,moomoo上的投資產品和服務是透過Moomoo Securities Malaysia Sdn. Bhd. 提供,該公司受馬來西亞證券監督委員會(SC)監管(牌照號碼︰eCMSL/A0397/2024) ,持有資本市場服務牌照 (CMSL) 。本內容未經馬來西亞證券監督委員會的審查。
Moomoo Technologies Inc., Moomoo Financial Inc., Moomoo Financial Singapore Pte. Ltd.,Futu Securities (Australia) Ltd, Moomoo Financial Canada Inc和Moomoo Securities Malaysia Sdn. Bhd., 是關聯公司。
- 分享到weixin
- 分享到qq
- 分享到facebook
- 分享到twitter
- 分享到微博
- 粘贴板
使用瀏覽器的分享功能,分享給你的好友吧